Journal
PATHOBIOLOGY
Volume 80, Issue 2, Pages 70-86Publisher
KARGER
DOI: 10.1159/000341640
Keywords
Cadherin; Calpain; Dantrolene; Dystrophin-glycoprotein complex; Heart; Intercalated disc; Myocardial dysfunction; Sepsis; Septic cardiomyopathy; Verapamil
Categories
Funding
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, FAPESP [07/58843-2, 09/17787-8, 09/54010-1, 10/19216-5]
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, CNPq [302387/20080, 470536/2008-0, 472419/2009-9]
- Fogarty International Training Grant [D43-TW007129]
- CNPq [1A]
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [09/17787-8, 10/19216-5] Funding Source: FAPESP
Ask authors/readers for more resources
Although myocardial depression is the predominant cause of death in severe sepsis/septic shock, it remains disputed whether the functional changes are a consequence of structural alterations. If we look at myocardial dysfunction from the perspective of a critically ill patient, there are a few questions to be asked: What causes myocardial dysfunction? What is the pathophysiology of cardiac dysfunction and death? Is there something that could be done to prevent the outcome? Each of these questions is interrelated and the answers will be more easily addressed if we continue to understand the basic mechanisms that are implicated. The principal mechanisms proposed for the pathogenesis of myocardial dysfunction support a prominent role for functional rather than anatomical abnormalities. However, attempts to reduce the high mortality in septic patients by manipulating the functional alterations have provided limited success. In recent years, the concept of septic cardiomyopathy has evolved, which implies alterations in the myocardial phenotype. This review includes an overview on the activation of the immune system and therapeutic approaches in sepsis, myocardial structural changes in the human septic heart, experimental models of sepsis, and cellular, molecular and functional myocardial changes seen in a variety of experimental sepsis models. The abnormal parameters discussed may emerge as therapeutic targets, for which modulation might provide beneficial effects on cardiovascular outcome and mortality in sepsis in the future. Copyright (C) 2012 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available